Micropos Medical (MPOS) Q3 2024 earnings summary

Executive summary

• First US order received from Medical University of South Carolina for Raypilot System, valued at over SEK 1.6 million, marking a breakthrough in the US market.

• Multiple clinical studies published, highlighting low side effects and ease of workflow integration for Raypilot System.

• Increased engagement with patient organizations and participation in key industry congresses to boost market presence.

Financial highlights

• Net sales for Jan–Sep 2024 reached SEK 2,084k, up from SEK 1,177k year-over-year; Q3 net sales SEK 72k, down from SEK 207k.

• Result after financial items for Jan–Sep 2024 was SEK -17,291k (vs. -17,803k); Q3 result SEK -5,655k (vs. -5,302k).

• Earnings per share for Jan–Sep 2024 was SEK -0.11 (vs. -0.13); Q3 EPS SEK -0.04 (unchanged year-over-year).

• Cash flow for the period was SEK 7,463k (vs. 7,966k); cash and cash equivalents at period end SEK 13,480k (vs. 11,393k).

• Equity at period end was SEK 14,700k (vs. 14,254k); 12.7 million new shares issued, raising SEK 22,351k.

Outlook and guidance

• Anticipated adoption of SBRT as standard treatment in Europe following PACE-B study publication, expected to drive demand for Raypilot System.

• Continued focus on expanding into routine care and broader healthcare markets, leveraging clinical evidence and patient organization partnerships.